Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Sleep Apnea Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 24-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 24-06-2019
Market Overview
The global sleep apnea devices market was valued at USD 5,956.9 million in 2018, and is estimated to be valued at USD 9,193.3 million in 2024, witnessing a CAGR of 7.5%. Few key factors that are driving the market include the increasing incidences of sleep apnea, increasing awareness among the patient population in developing countries, and favorable government initiatives.
According to the Sleep Apnea Organization, in 2017, more than 22 million Americans suffered from sleep apnea and 80% of moderate to severe sleep apnea cases were undiagnosed; worldwide, over 100 million people suffer from sleep apnea. Thus, the increasing incidence of sleep apnea is one of the factors responsible for the growth of the sleep apnea devices market.
It is known that obstructive sleep apnea (OSA) is a prevalent condition, which affects up to 20% of the world population. It is a serious and life-threatening sleep illness that is largely undiagnosed and untreated. However, various government initiatives are helping patients who suffer from OSA. For instance, in the United States, the American Sleep Apnea Association (ASAA) was founded in 1990, which is a non-profit organization that promotes awareness regarding sleep apnea, works for continuing improvements in treatments for this serious disorder, and advocates for the interests of sleep apnea patients. All these factors are boosting the market.
Scope of the Report
Sleep apnea is a serious sleep disorder, in which breathing repeatedly stops and starts. There are three main types of sleep apnea, obstructive sleep apnea, central sleep apnea, and complex sleep apnea syndrome. The factors, such as increased incidences of sleep apnea, increasing awareness among the patient population in the developing countries, favorable government initiatives, and upcoming technological advancements, are expected to drive the growth of the market over the forecast period.
Key Market Trends
Actigraphy Devices is Expected to Grow with Highest CAGR in the Diagnostic Devices Category
Actigraphy devices (actometer or actimeter) utilize a portable device, which is usually worn on the wrist that records physical movement over an extended period. This technology is being increasingly adopted in clinical settings, as actigraphy has the advantage of providing objective information on the sleep habits in patients’ natural sleep environment.
Since actigraphy is less invasive and less expensive than the PSG devices, it is a promising device for assessing sleep apnea treatment effects. It also can be used for follow-up, once the treatment has begun or to evaluate changes in sleep, over the course of the treatment period. The rising demand for actigraphy devices in sleep apnea is due to its cost effectiveness, as it facilitates non-intrusive 24-hours monitoring at home for extended periods. The sleep-wake is relatively easy and it does not require any installation.
North America Dominates the Market and Expected to continue its Dominance through the Forecast Period
North America currently dominates the market for sleep apnea devices and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the high incidence of sleep-disordered breathing (SDB) and rising aging population in the region. The United States holds the majority of the market in the North American region. According to the American Sleep Association, as of 2018, it was estimated that about 50-70 million adult population in the United States were found to have a sleep disorder, 48% were reported to be snoring, 37.9% were reported to be falling asleep during the day, unintentionally, and 4.7% were reported to be nodding off while driving. Insomnia is the most common specific sleep disorder, with short-term issues reported by about 30% of adults and chronic insomnia by 10%. Approximately 25 million adults in the United States have obstructive sleep apnea.
According to Sleep Zone, it was estimated that about 22 million Americans suffer from moderate to severe sleep apnea, out of which, approximately 3-7% of men and 2-5% of women were found to have had sleep apnea in 2018 in the United States.
Competitive Landscape
The sleep apnea devices market is highly competitive and consists of several major player, across the world. Further, with rising technological advancements and product innovations, mid-size and small scale companies are increasing their market presence by introducing new devices into the market with competitive prices. Companies, like Resmed, Fisher & Paykel Healthcare Limited, and Invacare Corporation, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Sleep Apnea
4.2.2 Increasing Awareness Among the Patient Population in the Developing Countries
4.2.3 Favorable Government Initiatives
4.2.4 Upcoming Technological Advancements
4.3 Market Restraints
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Diagnostic Devices
5.1.1 Polysomnography Devices (PSG)
5.1.2 Pulse Oximeters
5.1.3 Actigraphy Devices
5.2 By Therapeutic Devices
5.2.1 Positive Airway Pressure (PAP) Devices
5.2.1.1 Continuous Positive Airway Pressure (CPAP) Devices
5.2.1.2 Bi-level Positive Airway Pressure (BiPAP) Devices
5.2.2 Oxygen Devices
5.2.2.1 Oxygen Concentrators
5.2.2.2 Portable Oxygen Concentrators
5.2.2.3 Liquid Portable Oxygen
5.2.3 Oral Appliances
5.2.4 Adaptive Servo Ventilation (ASV) Devices
5.2.5 Masks and Accessories
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 South America
5.3.4.1 Brazil
5.3.4.2 Argentina
5.3.4.3 Rest of South America
5.3.5 Middle East & Africa
5.3.5.1 GCC
5.3.5.2 South Africa
5.3.5.3 Rest of Middle East & Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Fisher & Paykel Healthcare Limited
6.1.2 Koninklijke Philips NV
6.1.3 Invacare Corporation
6.1.4 Natus Medical Incorporated
6.1.5 Resmed
6.1.6 Cadwell Laboratories Inc.
6.1.7 Vyaire Medical Inc.
6.1.8 GE Healthcare
6.1.9 Nihon Kohden Corporation
6.1.10 Teleflex Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Diagnostic Devices
Polysomnography Devices (PSG)
Pulse Oximeters
Actigraphy Devices
By Therapeutic Devices
Positive Airway Pressure (PAP) Devices
Continuous Positive Airway Pressure (CPAP) Devices
Bi-level Positive Airway Pressure (BiPAP) Devices
Oxygen Devices
Oxygen Concentrators
Portable Oxygen Concentrators
Liquid Portable Oxygen
Oral Appliances
Adaptive Servo Ventilation (ASV) Devices
Masks and Accessories
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
Single Cell Analysis Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
The growth of the single cell analysis market is attributed to the technological advancements in single cell analysis products, increasing investments in cancer research, and rising biotechnology and biopharmaceutical industries in recent years.
Cancer is one of the major causes of deaths across the world, and there were 8.8 million victims in 2015, accounting for nearly one in six deaths. The disease has witnessed significant growth in the past few decades and is expected to rise rapidly over the forecast period. According to the World Health Organization (WHO), 10.9 million new cases of cancer were identified in 2002, which grew substantially over the next decade to approximately 14.1 million in 2012. An estimated 30% growth was observed over the decade. Moreover, WHO estimated the growth to increasing to 70% over the next two decades, worldwide. Circulating tumor cells are gaining increasing clinical attention since they are likely to enable the monitoring of cancer progression and adjustment of treatment. In such cases, single-cell sequencing analysis has found its application in search of better diagnostic and prognostic biomarkers. In recent years, multiple technologies for enrichment, isolation, as well as molecular and functional analysis of circulating tumor cells have been developed, such as single cell analysis. In 2014, the Clinical Research Infrastructure Initiative brought together several funding organizations, such as the Welcome Trust and Cancer Research UK, in partnership, led by the Medical Research Council (MRC), in order to invest over GBP 230 million for single-cell genomics for cancer studies.
In clinical diagnostics, single cell analysis is expected to standardize and automate workflows with valuable information for real-time monitoring of cancer and eventually new therapeutic strategies for the benefit of patients. This is expected to lead to more efficient and better analysis. Therefore, increasing investments in cancer research is considered as one of the major driving factors for the market over the forecast period.
Scope of the Report
As per the scope of this report, single cell analysis refers to the study of individual cells isolated from tissues in multicellular organisms. Study of living cells can increase the understanding of the interconnecting molecular events that are continually taking place within each cell.
Key Market Trends
Immunology Research Application is Expected to Grow with High CAGR During the Forecast Period
The cancer segment held the maximum share in 2018, owing to a high prevalence of cancer, initiatives for early detection, and increasing awareness regarding commercially available cancer diagnostics.
Immunology studies to aid in the early detection of therapeutic complications and increases the efficiency of the treatment. Furthermore, invasion of metabolic activities of single cells is increasing the adoption of its analytical tools, thus propelling the growth of immunology research segment.
North America Region Holds the Largest Market Share of Single Cell Analysis Market Market Currently and is Believed to Follow the Same Trend over the Forecast Period
The large share of the North American single cell analysis market is attributed to factors, such as increasing collaborations among prominent players, technological advancements, and expanding biotechnology and pharmaceutical industries. In recent years, several government initiatives have been launched that are supplementing the growth of the single cell analysis market in the region. For example, in 2015, the Precision Medicine Initiative was introduced to revolutionize the treatment of chronic diseases, including cancer.
The Asia-Pacific market is expected to witness the fastest growth during the forecast period, which is attributed to numerous government initiatives undertaken to improve healthcare infrastructure, availability of skilled professionals to operate advanced analytical instruments, and rising healthcare expenditure.
Competitive Landscape
The single cell analysis market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, Illumina Inc. and Bio-Rad Laboratories Inc. entered into a strategic collaboration in 2016, to co-develop comprehensive solution for single cell genomics
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Single Cell Analysis Products
4.2.2 Increasing Investments in Cancer Research
4.2.3 Rising Biotechnology and Biopharmaceutical Industries
4.3 Market Restraints
4.3.1 High Cost of Single Cell Analysis Instruments
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Cell Type
5.1.1 Human
5.1.2 Animal
5.1.3 Microbial
5.2 By Technique
5.2.1 Flow Cytometry
5.2.2 Next generation Sequencing
5.2.3 Polymerase Chain Reaction (PCR)
5.2.4 Microscopy
5.2.5 Mass Spectrometry
5.2.6 Other Techniques
5.3 By Application
5.3.1 Research Applications
5.3.1.1 Cancer Research
5.3.1.2 Immunology Research
5.3.1.3 Neurology Research
5.3.1.4 Stem Cell Research
5.3.1.5 Other Research Applications
5.3.2 Medical Application
5.3.2.1 Non-invasive Prenatal Diagnosis
5.3.2.2 In Vitro Fertilization
5.3.2.3 Circulating Tumor Cell Detection
5.4 By End User
5.4.1 Academic and Research Laboratories
5.4.2 Biotechnology and Pharmaceutical Companies
5.4.3 Hospital and Diagnostic Laboratories
5.5 Geography
5.5.1 North America
5.5.1.1 US
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 UK
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Beckman Coulter Inc.
6.1.3 Becton, Dickinson, and Company
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Fluidigm Corporation
6.1.6 GE Healthcare
6.1.7 Illumina Inc.
6.1.8 Merck KGaA
6.1.9 Qiagen NV
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Cell Type
Human
Animal
Microbial
By Technique
Flow Cytometry
Next generation Sequencing
Polymerase Chain Reaction (PCR)
Microscopy
Mass Spectrometry
Other Techniques
By Application
Research Applications
Cancer Research
Immunology Research
Neurology Research
Stem Cell Research
Other Research Applications
Medical Application
Non-invasive Prenatal Diagnosis
In Vitro Fertilization
Circulating Tumor Cell Detection
By End User
Academic and Research Laboratories
Biotechnology and Pharmaceutical Companies
Hospital and Diagnostic Laboratories
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Rheumatoid Arthritis Drugs Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 118 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 118 pages
- Published: 07-06-2019
Market Overview
The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals. The major factors that fuel the growth of the market are the rising incidence of rheumatoid arthritis and the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, with the increasing geriatric population, the market is expected to experience growth in the coming years.
There are also several therapeutics and medications that have been developed in the recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid arthritis drugs management is generally associated with a high cost. Most commonly used drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. Thus biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines. However the costs of rheumatoid arthritis drugs and NSAIDs are less than biologics. Thus, growing availability and awareness of safer drugs are anticipated to increase the global rheumatoid arthritis drugs market.
Scope of the Report
As per the scope of the report, rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the joints of the body. Rheumatoid arthritis disease mostly affects the joints of the hand, wrists, elbows, knees, and ankles. It also affects the cardiac and respiratory system, and is known as systemic disease. It thus exhibits symptoms of swelling, redness, and warmth in the affected areas. Owing to the rise in the adoption of sedentary lifestyle, the patient pool is expected to witness a healthy growth.
Key Market Trends
NSAIDs Segment by Drug Class is Expected to be the Largest Segment During the Forecast Period
NSAIDs are being widely utilized for the symptomatic treatment of rheumatic disorders. DMARDs are also considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Unlike conventional DMARDs, such as NSAIDs, which simply give symptomatic relief, biologic drugs are more efficient in the management of rheumatoid arthritis.
Asia-Pacific is Witnessing High Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific market is projected to witness high growth during the forecast period, due to increasing healthcare expenditure. Moreover, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world. The increase in the incidence of rheumatoid arthritis disease is also expected to fuel the market in the region during the forecast period.
Competitive Landscape
A majority of rheumatoid arthritis drug products are being manufactured by key players. The market leaders in this industry have established their position in the market, and these manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in the Asia-Pacific region are witnessing the entry of small players.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1. Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Launch of New Biosimilars
4.2.2 Rising Prevalence of Arthritis
4.2.3 Increase in the Acceptance of Biopharmaceuticals
4.3 Market Restraints
4.3.1 Patent Expiration of Blockbuster Drugs
4.3.2 Alternative Treatment Options
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 By Type of Molecule
5.1.1 Pharmaceuticals
5.1.2 Biopharmaceuticals
5.2 By Drug Class
5.2.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.2 Corticosteroids
5.2.3 Analgesics
5.2.4 Other Drug Classes
5.3 By Sales Channel
5.3.1 Prescription
5.3.2 Over-the-counter (OTC)
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. Competitive Landscape
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amgen Inc.
6.1.3 Bayer AG
6.1.4 Boehringer Ingelheim GmbH
6.1.5 Bristol-Myers Squibb Company
6.1.6 Celgene Corporation
6.1.7 F. Hoffmann-La Roche AG
6.1.8 Johnson & Johnson
6.1.9 Merck & Co. Inc.
6.1.10 Novartis AG
7. Market Opportunities and Future Trends
- By Type of Molecule
Pharmaceuticals
Biopharmaceuticals
By Drug Class
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Analgesics
Other Drug Classes
By Sales Channel
Prescription
Over-the-counter (OTC)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe - Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Revenue Cycle Management Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 07-06-2019
Market Overview
The growth of the revenue cycle management (RCM) market is attributed to the increase in government initiatives to boost the adoption of RCM solutions, increasing revenue loss due to billing errors, and increasing adoption of EHR/EMR.
Revenue for healthcare providers depends on the accurate processing of medical claims. For improving the financial outcome, a healthcare organization needs to maintain a quality revenue cycle and insurance billing. The revenue cycle management team comprises of accounts receivable (A/R) management and denial management. With mounting pressure on hospitals to reduce cost, most of the care providers are losing revenue due to claim denials and their failure to submit or delay the denied claim. This has given an opportunity for specialty firms that provide revenue cycle management service.
Most hospitals are now dependent on third-party providers for denial management service, as they lack in the expert knowledge and the time to manage the reimbursement process. Most common billing errors include failure to verify insurance, filing an incomplete claim, coding errors, lack of specificity, and missing filing deadlines. Most of the care providers are now addressing the challenge by working with third-party medical billing professionals, who are expert in the overall revenue cycle management. With their expertise, these providers are able to increase the cash flow of their clients, which was otherwise neglected by the hospitals to resubmit the denied claims. It is estimated that over 90% of the claim denials can be prevented with support from providers (who have systems) and knowledge experts in this field. From the above, it can be concluded that the revenue loss to hospitals due to billing errors can be prevented by specialty revenue cycle management service providers. Thereby, this factor is expected to drive the market studied over the forecast period.
Scope of the Report
As per the scope of this report, the term revenue cycle management refers to solutions that support various hospitals and medical facilities to increase their revenue, by addressing the mistakes in billing, and by helping with efficient billing, documentation, and claim management.
Key Market Trends
Cloud-based is the Segment Under Deployment that is Expected to grow Fastest During the Forecast Period
The web-based segment held a maximum share in 2018 as it is installed off-site and is supervised by a third party. It is used over the internet and with a web browser, which does not require any additional storage or hardware. So, the data can be retrieved by various healthcare providers from different geographical locations.
The cloud-based segment is forecasted to show significant growth during the forecast period due to the flexibility and scalability offered by these solutions. The cloud-based delivery model makes the software extremely flexible regarding scalability (pay-as-you-go storage utilization). It simplifies and consolidates storage resources to reduce cost and enhance workflow, by eliminating departmental silos of clinical information. The storage and server power for the organization is hosted off-premise. The cloud vendor provides all the off-premise system support resources. This feature about cloud technology is a key market driver.
North America holds the Largest Market Share of the Revenue Cycle Management Market Currently and is Believed to Follow the Same Trend over the Forecast Period
The North American healthcare revenue cycle management market dominated the global market and is estimated to show a similar trend during the forecast period. This growth is due to factors like significant changes in regulations that have largely affected the finances, organization, and delivery of healthcare services. Most US healthcare providers are deploying revenue cycle management (RCM) systems that reduce the time taken for receiving payment after providing a service. The RCM that automates many activities previously done manually is saving time, which is a major factor for the growth of the market.
Competitive Landscape
The RCM market is moderately competitive, and consists of several major players, including Allscripts Healthcare Solutions, Athenahealth, Cerner Corporation, etc. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, in April 2015, CareCloud entered into a partnership with Marshfield Clinic’s IT arm. CareCloud merged its medical billing software and services and Concierge practice management with Marshfield Clinic’s clinical solutions, such as electronic health record, population health management tool, and patient portal. The strategic partnership enabled the company to capitalize on market opportunities and rendered the company with profits.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Initiatives to Boost the Adoption of RCM Solutions
4.2.2 Increasing Revenue Loss Due to Billing Errors
4.2.3 Increasing Adoption of EHR/EMR
4.3 Market Restraints
4.3.1 High Pricing and Maintenance of RCM Solutions
4.3.2 Lack of Proper IT infrastructure
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Deployment
5.1.1 Web-based
5.1.2 Cloud-based
5.1.3 On-premise
5.2 By Function
5.2.1 Claims and Denial Management
5.2.2 Medical Coding and Billing
5.2.3 Electronic Health Record (EHR)
5.2.4 Clinical Documentation Improvement (CDI)
5.2.5 Insurance
5.2.6 Other Functions
5.3 By End User
5.3.1 Hospitals
5.3.2 Laboratories
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions
6.1.2 athenahealth, Inc.
6.1.3 Cerner Corporation
6.1.4 Conifer Health Solutions, LLC
6.1.5 Constellation Software
6.1.6 eClinicalWorks
6.1.7 Epic Systems Corporation
6.1.8 GE Healthcare
6.1.9 GeBBs Healthcare Solutions, Inc.
6.1.10 Mckesson Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Deployment
Web-based
Cloud-based
On-premise
By Function
Claims and Denial Management
Medical Coding and Billing
Electronic Health Record (EHR)
Clinical Documentation Improvement (CDI)
Insurance
Other Functions
By End User
Hospitals
Laboratories
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
]Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Retinoblastoma Treatment Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 13-06-2019
Market Overview
Global Retinoblastoma Treatment market was valued at USD 2297.13 million in 2018, and is estimated to be valued at USD 3001.78 million in 2024, witnessing a CAGR of 4.56%. certain factors that are driving the market growth include remission and the chance of recurrence, and increasing public awareness.
Recurrent retinoblastoma occurs, when cancer comes back after it has been treated and diagnosed. Both extraocular and intraocular retinoblastoma might have probable chances of remittance.
Generally, the likelihood of relapse and formation of secondary tumors increases with the genetic nature of the disease. Patients with non-hereditary or sporadic retinoblastoma are not as susceptible to relapse, as hereditary ones. Although, the cure rate for retinoblastoma is quite high, the exact cure rate is dependent on the extent of the disease and chances of recurrence. The increasing number of treatment procedures drive the retinoblastoma treatment market.
In addition, improving awareness about retinoblastoma is a worthwhile goal, and any eye complaint merits careful attention from all nursing and medical personnel. Improving awareness regarding retinoblastoma is especially important in developing countries, as the incidences of eye cancer are increasing, and many children die undiagnosed or have advanced disease at presentation, due to delay in referral to an oncology centre. Retinoblastoma educational and public awareness campaigns have been shown to increase referrals, decrease rates of advanced disease, and improve outcomes in low and middle-income countries.
However, side effects of retinoblastoma surgery, radiation therapy to the head and certain chemotherapy drugs, such as cisplatin and carboplatin (Paraplatin, Paraplatin AQ), may cause hearing loss when they are given to very young children. The other eye problems include difficulty in judging distance between objects and difficulty seeing to the side (peripheral vision). Eye problems can also lead to changes in balance.
Scope of the Report
Retinoblastoma is the most common cancer among children, which starts in the retina. It generally develops before the age of 5. One out of three children with retinoblastoma develops cancer in both eyes. The most common symptom of retinoblastoma is a visible whiteness in the pupil, called cat’s eye reflex or leukocoria.
Key Market Trends
Non-hereditary Retinoblastoma is Expected to hold its Highest Market Share in the Retinoblastoma Type Segment
In the Retinoblastoma type segment of the Retinoblastoma treatment market, the non-hereditary retinoblastoma (NHR) is expected to have the largest market size and is likely to witness a CAGR of 3.82% in the forecast period.
Non-hereditary retinoblastoma (NHR), also known as sporadic retinoblastoma, is the more prevalent form of retinoblastoma. According to the American Cancer Society, 67% of reported cases (in the United States) of retinoblastoma in pediatrics are non-hereditary or sporadic.
The NHR is mostly a pediatric disease, and according to the American Cancer Society, the survival rates post diagnosis is approximately 90%. According to the Union for International Cancer Control, the average age-adjusted incidence rate of retinoblastoma in the United States and Europe is 2-5/106 children (approximately one in 14,000 – 18,000 live births).
The market for NHR is expected to grow tremendously over the forecast period, primarily due to the higher incidence rate, when compared to hereditary retinoblastoma. Additionally, factors, like high survival rates post diagnosis in developed regions, like the United States, are likely to add to the global market growth.
Asia-Pacific Dominates the Market and Expected to do Same in the Forecast Period
Asia-Pacific currently dominates the market for Retinoblastoma Treatment and is expected to continue its strong hold for a few more years. This region is expected to increase its market share in the future owing to the fact that, retinoblastoma (Rb) is the most common primary intraocular malignancy of infancy and childhood, and seriously endangers the vision and life of children.
According to the United Nations Survey in 2016, China was only second to that in India, in the prevalence of Rb in APAC countries. Similarly, according to the Japanese Journal of Ophthalmology, in 2018, the average occurrence frequency for retinoblastoma was 1:16,823 births/year and at diagnosis, 89.0% of the patients were aged younger than 3 years and 41.0% were aged younger than 1 year.
Furthermore, in countries like India, current treatment modalities of systemic chemotherapy and focal treatment have contributed significantly to disability limitation and patient survival and there is less knowledge on the genetics of the retinoblastoma gene and its protein, and there is potential for developing targeted molecular therapies.
Competitive Landscape
The Retinoblastoma Treatment market is moderately competitive and consists of a considerable number of major players. Companies like B Baxter International Inc., GlaxoSmithKline, Pfizer Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, Merck & Co., Cadila Pharmaceuticals, and Teva Pharmaceutical, among others, are expected to hold the substantial market share in the Retinoblastoma Treatment market.
Various developments have recently been taking place in the market. For example, in June 2018, GSK completed the Consumer Healthcare buyout of Novartis.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Remission and the Chance of Recurrence
4.2.2 Increasing Public Awareness
4.3 Market Restraints
4.3.1 Small Patient Pool
4.3.2 Side Effects of Retinoblastoma Surgery
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Surgery
5.1.2 Radiation therapy
5.1.3 Laser Therapy (Photocoagulation)
5.1.4 Cryotherapy
5.1.5 Thermotherapy
5.1.6 Chemotherapy
5.1.6.1 Carboplatin
5.1.6.2 Cisplatin
5.1.6.3 Vincristine
5.1.6.4 Etoposide
5.1.6.5 Cyclophosphamide
5.1.6.6 Topotecan
5.1.6.7 Doxorubicin
5.1.6.8 Cyclosporine
5.1.6.9 Melphalan
5.1.7 Opthalmic Artery Infusion Chemotherapy
5.1.8 High-dose Chemotherapy and Stem Cell Transplant
5.2 By Type of Retinoblastoma
5.2.1 Non-hereditary Retinoblastoma
5.2.2 Hereditary Retinoblastoma
5.3 By Type of Staging
5.3.1 Intraocular Retinoblastoma
5.3.2 Extraocular Retinoblastoma
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baxter International Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Cadila Pharmaceuticals
6.1.4 GlaxoSmithKline plc
6.1.5 Johnson & Johnson
6.1.6 Merck & Co.
6.1.7 Novartis AG
6.1.8 Pfizer Inc.
6.1.9 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Treatment Type
Surgery
Radiation therapy
Laser Therapy (Photocoagulation)
Cryotherapy
Thermotherapy
Chemotherapy
Carboplatin
Cisplatin
Vincristine
Etoposide
Cyclophosphamide
Topotecan
Doxorubicin
Cyclosporine
Melphalan
Opthalmic Artery Infusion Chemotherapy
High-dose Chemotherapy and Stem Cell Transplant
By Type of Retinoblastoma
Non-hereditary Retinoblastoma
Hereditary Retinoblastoma
By Type of Staging
Intraocular Retinoblastoma
Extraocular Retinoblastoma
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Renal Biomarkers Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 119 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 119 pages
- Published: 07-06-2019
Market Overview
The global renal biomarkers market was valued at USD 1,023.04 million in 2018, and is estimated to be valued at USD 1,552.60 million in 2024, witnessing a CAGR of 7.20%. The key factors propelling the growth of this market are the rising prevalence of various kidney-related diseases, the high prevalence of diabetes and high blood pressure, which are the leading causes of renal diseases, and rapid technological advancements in the field of genetics.
Advancements in the field of genetic technology during the last decade have enlightened people’s knowledge regarding genetic regulatory pathways related to renal biomarkers. Due to rapid advances in genomic technologies, genetics analyses have become essential in clinical practice and research. Moreover, with the development of computer technology, renal biomarkers testing has become widely accessible and feasible to perform, even in small-sized laboratories. Recent advances in genetics have created opportunities to study kidney disease in a variety of platforms, applied to human populations. Renal biomarkers can also be integrated into genetic-level technological advancements for the detection, diagnosis, and treatment of kidney diseases. These rapid advances in genetics led to the development of more advanced renal biomarkers for treating kidney diseases, which ultimately drives the market.
Scope of the Report
In the report, a detailed analysis of the global renal biomarkers market is provided. The market is evaluated by collating revenues generated across segments, categorized by biomarker type, diagnostic technique, and end user.
Key Market Trends
Functional Biomarker is Expected to hold its Highest Market Share in the Biomarker Type Segment
In the biomarker type segment of the market, the functional biomarker is believed to have the largest market size and is expected to witness a CAGR of 6.94% during the forecast period.
Chronic kidney disease (CKD) has become a public health problem. According to the National Institute of Diabetes, Digestives and Kidney Diseases, the overall prevalence of CKD in the general population is approximately 14%, and around 6,61,000 Americans have kidney failure. Currently, the diagnosis of CKD is made usually on the levels of serum creatinine (SCr). The serum creatinine, a functional biomarker, dominates the market of renal biomarkers, owing to the high prevalence rate of CKD and high presence and knowledge of serum creatinine biomarker.
North America Dominates the Market and Expected to do the Same in the Forecast Period
North America currently dominates the market for renal biomarkers and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Over the past decade, there has been a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures. Molecular biomarkers are expected to be identified and validated in drug development and be used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.
Competitive Landscape
The renal biomarkers market is highly competitive and consists of several major players, along with multiple smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies with affordable prices. Companies, like Thermofisher Scientific, Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche, and BioMérieux, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Various Kidney-related Diseases
4.2.2 The High Prevalence of Diabetes and High Blood Pressure, the Leading Cause of Renal Diseases
4.2.3 Rapid Technological Advances In The Field Of Genetics
4.3 Market Restraints
4.3.1 Issues Related to Regulatory and Reimbursement Systems
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Biomarker Type
5.1.1 Functional Biomarker
5.1.1.1 Serum Creatinine
5.1.1.2 Serum Cystatin C
5.1.1.3 Urine Albumin
5.1.2 Up-regulated Protein
5.1.2.1 Neutrophil Gelatinase-Associated Lipocalin (NGAL)
5.1.2.2 Kidney Injury Molecule-1
5.1.2.3 INTERLEUKIN-18
5.2 Diagnostic Technique
5.2.1 Enzyme-linked Immunosorbent Assay
5.2.2 Particle-enhanced Turbidimetric Immunoassay (PETIA)
5.2.3 Colorimetric Assay
5.2.4 Chemiluminescent Enzyme Immunoassay (CLIA)
5.2.5 Liquid Chromatography Mass Spectrometry (LS-MS)
5.3 End User
5.3.1 Hospital
5.3.2 Diagnostic Laboratory
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Beckman Coulter Inc. (Danaher Corporation)
6.1.2 Thermo Fisher Scientific Inc.
6.1.3 Abbott Molecular Inc. (Abbott Laboratories Ltd)
6.1.4 Bioporto AS
6.1.5 Astute Medical Inc.
6.1.6 Randox Laborotories Ltd
6.1.7 Siemens Healthcare
6.1.8 Cobo Scientific Biomedical Research
6.1.9 F. Hoffmann-La Roche Ag
6.1.10 Biomerieux
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Biomarker Type
Functional Biomarker
Serum Creatinine
Serum Cystatin C
Urine Albumin
Up-regulated Protein
Neutrophil Gelatinase-Associated Lipocalin (NGAL)
Kidney Injury Molecule-1
INTERLEUKIN-18
Diagnostic Technique
Enzyme-linked Immunosorbent Assay
Particle-enhanced Turbidimetric Immunoassay (PETIA)
Colorimetric Assay
Chemiluminescent Enzyme Immunoassay (CLIA)
Liquid Chromatography Mass Spectrometry (LS-MS)
End User
Hospital
Diagnostic Laboratory
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America